Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type 1.

Abstract	We previously reported markedly reduced (-76%) dopamine (DA) levels in the putamen of seven patients with spinocerebellar ataxia type 1 (SCA1) who had no evidence of nigral cell loss or parkinsonism. To determine whether the DA reduction was accompanied by loss of DA nerve terminals, we measured levels of the DA transporter ([3H]WIN, 35,428 binding; DA transporter protein) and the vesicular monoamine transporter ([3H]DTBZ binding) in the putamen of these patients. As compared with the controls (n = 14), mean putamen concentrations of [3H]WIN 35,428 binding (-45%), dopamine transporter protein (-61%), and [3H]DTBZ binding (-48%) were significantly reduced in this SCA1 subgroup. We conclude that the degeneration in nigrostriatal DA neurons begins at the nerve ending in SCA1.
Authors	S J Kish, M Guttman, Y Robitaille, M el-Awar, L J Chang, A I Levey
Journal	Neurology (Neurology) Vol. 48 Issue 4 Pg. 1109-11 (Apr 1997) ISSN: 0028-3878 [Print] United States
PMID	9109912 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References	Biomarkers Carrier Proteins Dopamine Plasma Membrane Transport Proteins Dopamine Uptake Inhibitors Membrane Glycoproteins Membrane Transport Proteins Nerve Tissue Proteins dihydrotetrabenazine (1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester Cocaine Dopamine Tetrabenazine
Topics	Adult Biomarkers Cadaver Carrier Proteins (metabolism) Cocaine (analogs & derivatives, metabolism) Corpus Striatum (metabolism) Dopamine (metabolism) Dopamine Plasma Membrane Transport Proteins Dopamine Uptake Inhibitors (metabolism) Humans Membrane Glycoproteins Membrane Transport Proteins Middle Aged Nerve Endings (metabolism) Nerve Tissue Proteins Putamen (metabolism) Spinocerebellar Degenerations (metabolism, pathology) Substantia Nigra (pathology) Tetrabenazine (analogs & derivatives, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!